The year is coming to a close, and it’s hard to believe we now only have one month left of 2012! Time flies when you’re having fun, and the many happy posts we found around the diabetes blogosphere show that’s what we’ve all been doing this past month!
Of course, November is the biggest D-Month of the year, in which diabetes awareness is on the world’s stage. With World Diabetes Day itself on Nov. 14…
At last week’s Diabetes Technology Society Meeting in Bethesda, MD, Dexcom’s VP of Science & Technology Tom Peyser presented a brand new metric for glycemic variability based on CGM data that may be much more useful and easier to understand than Standard Deviation.
“Glycemic variability” is of course a fancy name for how out-of-control your blood sugar levels are. Swinging between severe ups and downs all the time (high variability) puts you at risk for…
Last week, a virtual who’s-who of about 500 researchers and scientists working on diabetes technologies gathered in Bethesda, MD, for the 12th annual meeting of the Diabetes Technology Society. More than 70 presenters gave talks, mostly introducing new research, over the course of three days.
Myself and DOC consultant/advocate Kelly Close both gave talks about the power of patient-led social media (!)
But the most exciting things this year, to my mind, appeared to be…
Last Wednesday, diabetes researchers and advocates from around the country convened in Washington, DC, for an FDA hearing on the Artificial Pancreas with the aim of making this pipe dream a reality. The point of the hearing was to allow JDRF and other stakeholders — researchers, industry reps, and patients — a chance to provide input on the Artificial Pancreas Project, in particular “recommendations to ensure the safe and effective testing of artificial pancreas technology…
Read more »
Today, just a sampling of some of the interesting stuff presented at last week’s Diabetes Technology Society meeting, that will be out on the market in … um… some years from now (?):
IN-105 Oral Insulin for Type 2 diabetes – Biocon Limited, apparently India’s premier biotechnology company, has been developing oral insulin tablets for some years now. Positive research results were announced last year. And they’re not just for basal use, either. Studies confirmed…
Read more »